TY - JOUR
T1 - Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis
T2 - Statement of the council of regional networks for genetic services
AU - Therrell, Bradford L.
AU - Hannon, W. Harry
AU - Pass, Kenneth A.
AU - Lorey, Fred
AU - Brokopp, Charles
AU - Eckman, James
AU - Glass, Mike
AU - Heidenreich, Randy
AU - Kinney, Shari
AU - Kling, Sydney
AU - Landenburger, Gretchen
AU - Meaney, F. John
AU - Mccabe, Edward R.B.
AU - Panny, Susan
AU - Schwartz, Marion
AU - Shapira, Emmanuel
N1 - Funding Information:
CORN is currently funded in part by Grant MCJ -361011-01-0 from the Genetic Services Branch, Maternal and Child Health Bureau, Health Resources and Services Administration (HRSA), Public Health Service, U.S. Department of Health and Human Services. The development of this guideline also included the participation of the Centers for Disease Control and Prevention (CDC) and the Association of State and Territorial Public Health Laboratory Directors (ASTPHLD), Washington, DC. Comments about the contents of the document should be submitted to the CORN Office, Emory University School of Medicine, Pediatrics/ Medical Genetics, 2040 Ridgewood Drive, Atlanta, GA 30322. These guidelines will be periodically reviewed and updated as appropriate. The guidelines were approved for distribution on April 2, 1995. Sue Triesch is acknowledged for her help in manuscript preparation.
PY - 1996
Y1 - 1996
N2 - These guidelines provide scientific information for policy development by state health departments considering appropriate use of newborn screening specimens after screening tests are finished. Information was collected, debated, and formulated into a policy statement by the Newborn Screening Committee of the Council of Regional Networks for Genetic Services (CORN), a federally funded national consortium of representatives from 10 regional genetics networks. Newborn screening programs vary widely in approaches and policies concerning residual dried blood spot samples (DBS) collected for newborn screening. Recognition of the epidemiological utility of DBS samples for HIV seroprevalence surveys and a growing interest in DBSs for DNA analysis has intensified consideration of issues regarding retention, storage, and use of residual DBS samples. Potentially these samples provide a genetic material 'bank' for all newborns nationwide. Their value as a resource for other uses has already been recognized by scientists, administrators, and judicial officials. Programs should promulgate rules for retention and use of residual newborn screening DBS samples based on scientifically valid information. Banking of newborn samples as sources of genetic material should be considered in light of potential benefit or harm to society.
AB - These guidelines provide scientific information for policy development by state health departments considering appropriate use of newborn screening specimens after screening tests are finished. Information was collected, debated, and formulated into a policy statement by the Newborn Screening Committee of the Council of Regional Networks for Genetic Services (CORN), a federally funded national consortium of representatives from 10 regional genetics networks. Newborn screening programs vary widely in approaches and policies concerning residual dried blood spot samples (DBS) collected for newborn screening. Recognition of the epidemiological utility of DBS samples for HIV seroprevalence surveys and a growing interest in DBSs for DNA analysis has intensified consideration of issues regarding retention, storage, and use of residual DBS samples. Potentially these samples provide a genetic material 'bank' for all newborns nationwide. Their value as a resource for other uses has already been recognized by scientists, administrators, and judicial officials. Programs should promulgate rules for retention and use of residual newborn screening DBS samples based on scientifically valid information. Banking of newborn samples as sources of genetic material should be considered in light of potential benefit or harm to society.
UR - http://www.scopus.com/inward/record.url?scp=15844396182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15844396182&partnerID=8YFLogxK
U2 - 10.1006/bmme.1996.0017
DO - 10.1006/bmme.1996.0017
M3 - Article
C2 - 8733889
AN - SCOPUS:15844396182
SN - 1077-3150
VL - 57
SP - 116
EP - 124
JO - Biochemical and Molecular Medicine
JF - Biochemical and Molecular Medicine
IS - 2
ER -